Phase III QUIREDEX Trial of Lenalidomide (Len) and Dexamethasone (Dex) and Phase II Trial of Carfilzomib and Len/Dex in High-Risk Smoldering MM


Phase III QUIREDEX Trial of Lenalidomide (Len) and Dexamethasone (Dex) and Phase II Trial of Carfilzomib and Len/Dex in High-Risk Smoldering MM
Slides from presentations at ASH 2014 and transcribed comments from a recent interview with Ola Landgren, MD, PhD (2/9/15)
Mateos MV et al. Long term follow-up on the treatment of high risk smoldering myeloma with lenalidomide plus low dose dex (Rd) (phase III Spanish trial): Persistent benefit in overall survival. Proc ASH 2014;Abstract 3465.

Landgren O et al. Carfilzomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma: Final results from the NCI phase 2 pilot study. Proc ASH 2014;Abstract 4746.

Dr Landgren is Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center in New York, New York.